Thomas John Charles 4

What Happened
Thomas John Charles, Executive Vice President and General Counsel of Krystal Biotech (KRYS), sold 642 shares of the company's common stock on May 26, 2026. The shares were disposed at $302.03 each, for proceeds of approximately $193,903. This was a sale (not a purchase) and appears to be a routine disposition under a prearranged trading plan.

Key Details

• Transaction date: May 26, 2026; reported on Form 4 filed May 27, 2026.
• Transaction type/code: Sale (S) — reported as an open market or private sale.
• Price and amount: 642 shares at $302.03 per share; total ≈ $193,903.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Charles on Feb 23, 2026; the plan runs through Dec 31, 2026 (or ends earlier on plan terms) and will terminate upon completion of the planned sales.
• Filing timeliness: The Form 4 was filed the day after the trade (May 27 for a May 26 trade), which is consistent with normal Form 4 reporting timing.

Context
A sale executed under a Rule 10b5-1 plan means the transaction was prearranged and scheduled in advance, which is commonly treated as a routine liquidity event rather than an ad hoc signal about the company's prospects. As always, sales by insiders are informative about their personal portfolio moves but do not by themselves indicate management view on future company performance.